Hemedex, Inc., was founded in 2000 to commercialize a proprietary platform technology conceived at the Massachusetts Institute of Technology (MIT) to quantify tissue perfusion (i.e., blood flow at the capillary level). This technology addresses the need for real-time, prognostic data in complex medical and surgical procedures. These complex procedures often involve compromised vasculature and other serious pathophysiology, resulting in high rates of morbidity, delayed recuperation, poor patient outcome and higher overall costs. Hemedex's patented technology can provide an early warning of impending tissue ischemia, and it can help target appropriate therapies rapidly and accurately. In doing so, it aides in stemming some of the ill effects listed above by providing clinicians with a powerful tool to generate valuable prognostic data.